This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC